Jordana Grazziela Alves Coelho-Dos-Reis Selected Research

Tropical Spastic Paraparesis (Tropical Spastic Paraplegia)

1/2015

Immunological signature of the different clinical stages of the HTLV-1 infection: establishing serum biomarkers for HTLV-1-associated disease morbidity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jordana Grazziela Alves Coelho-Dos-Reis Research Topics

Disease

7	Infections 12/2023 - 06/2010
3	COVID-19 12/2023 - 01/2023
2	Leprosy (Hansen's Disease) 01/2024 - 12/2018
2	Sickle Cell Anemia (Hemoglobin S Disease) 01/2023 - 04/2022
2	Visceral Leishmaniasis (Kala Azar) 01/2022 - 10/2009
2	Chagas Disease (American Trypanosomiasis) 02/2012 - 06/2011
1	Reinfection 01/2023
1	Thromboembolism 01/2023
1	Chronic Disease (Chronic Diseases) 01/2023
1	Yellow Fever 01/2023
1	Cytokine Release Syndrome 01/2023
1	Hepatitis 01/2023
1	Virus Diseases (Viral Diseases) 01/2023
1	Human Influenza (Influenza) 01/2023
1	Osteomyelitis 04/2022
1	Inflammation (Inflammations) 04/2022
1	Leg Ulcer 04/2022
1	Anemia 01/2022
1	Dengue (Dengue Fever) 01/2022
1	Leishmaniasis 01/2022
1	Parasitic Diseases (Parasitic Disease) 01/2022
1	Chronic Hepatitis C 01/2021
1	Coinfection 01/2021
1	Fibrosis (Cirrhosis) 01/2021
1	Congenital Toxoplasmosis 12/2017
1	Communicable Diseases (Infectious Diseases) 01/2017
1	Spinal Cord Diseases 01/2015
1	Tropical Spastic Paraparesis (Tropical Spastic Paraplegia) 01/2015
1	Disease Progression 06/2010

Drug/Important Bio-Agent (IBA)

8	Biomarkers (Surrogate Marker)IBA 01/2024 - 01/2015
6	CytokinesIBA 01/2024 - 01/2015
6	Immunoglobulin G (IgG)IBA 01/2022 - 10/2009
5	ChemokinesIBA 01/2024 - 01/2015
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2024 - 01/2022
3	Antiviral Agents (Antivirals)IBA 12/2023 - 01/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2023 - 01/2021
2	VaccinesIBA 01/2023 - 01/2022
2	AntibodiesIBA 06/2010 - 10/2009
1	Immunodominant EpitopesIBA 01/2023
1	GlycolipidsIBA 01/2023
1	Hydroxyurea (Hydrea)FDA LinkGeneric 01/2023
1	Soaps (Soap)IBA 04/2022
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 04/2022
1	Local Anti-Infective Agents (Antiseptics)IBA 04/2022
1	Peptides (Polypeptides)IBA 01/2022
1	AntigensIBA 01/2022
1	Hemoglobins (Hemoglobin)IBA 01/2022
1	Interleukin-17 (Interleukin 17)IBA 01/2022
1	Interleukin-15 (Interleukin 15)IBA 01/2021
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2021
1	SimeprevirIBA 01/2021
1	N- (8- aminohexyl)- 5- iodonaphthalene- 1- sulfonamide (W8)IBA 01/2021
1	daclatasvirIBA 01/2021
1	SofosbuvirIBA 01/2021
1	HLA-DR Antigens (HLA-DR)IBA 12/2018
1	Immunoglobulin M (IgM)IBA 12/2017
1	Thomsen-Friedenreich antibodiesIBA 12/2017
1	LeukotrienesIBA 01/2015
1	tax Gene Products (tax Gene Product)IBA 06/2010
1	Proteins (Proteins, Gene)FDA Link 06/2010

Therapy/Procedure

3	Therapeutics 01/2023 - 01/2021
1	Intranasal Administration 01/2023
1	Critical Care (Surgical Intensive Care) 01/2023
1	Aftercare (After-Treatment) 01/2022
1	Microspheres (Microsphere) 01/2022
1	Immunotherapy 01/2017
1	Drug Therapy (Chemotherapy) 06/2011